Also trades as: NAMSW (NASDAQ) · $vol 0M
NAMS NASDAQ
NewAmsterdam Pharma Company N.V.
1W: -11.8%
1M: -18.1%
3M: -24.6%
YTD: -35.2%
1Y: -15.2%
3Y: +115.5%
5Y: +131.0%
$22.80
+0.94 (+4.30%)
Weekly Expected Move ±7.8%
$19
$21
$23
$25
$26
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.7B
52W Range21.23-42.205
Volume1,596,530
Avg Volume1,278,283
Beta0.10
Dividend—
Analyst Ratings
Company Info
CEOMichael Harvey Davidson Facp.
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-09
Websitenewamsterdampharma.com
Gooimeer 2-35
Naarden, NH 1411 DC
NL
Naarden, NH 1411 DC
NL
31 35 206 2971
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerâs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Latest News
Biggest stock movers Tuesday: ZIM, NVS, and more
Novo Nordisk faces fresh setback as it halts two heart drug trials
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Smither John W | S-Sale | 1,600 | $25.32 | 2026-09-04 |
| Gunning Robert Willi | A-Award | 3,200 | — | 2026-09-01 |
| Gunning Robert Willi | A-Award | 14,000 | $24.92 | 2026-09-01 |
| Kastelein Johannes J | M-Exempt | 125,000 | — | 2026-08-24 |
| Kastelein Johannes J | S-Sale | 125,000 | $26.91 | 2026-08-24 |